The increasing number of cases of serogroup C meningococcal disease in Scotland in the late 1990s coincided with the availability of a new meningococcal conjugate serogroup C (MCC) vaccine that, from 1999 onwards, was offered to all individuals aged !20 years. Annual incidence rates between 1994 and 2003 were calculated in 3 age groups (!5 years old; 5-19 years old; and у20 years old), and Poisson regression models were used to verify disease trends over time. Dramatic reductions ( ) in the incidence of serogroup C meningococcal P ! .05 disease were seen in target age groups: from 15.8 incidents per 100,000 subjects in 1999 (95% confidence interval [CI], 11.3-20.3) to 0.7 incidents per 100,000 subjects in 2001 (95% CI, Ϫ0.3 to 1.6), for subjects !5 years old, and from 6.7 incidents per 100,000 subjects in 1999 (95% CI, 5.1-8.3) to 1.5 incidents per 100,000 subjects in 2001 (95% CI, 0.7-2.3), for subjects 5-19 years old. An increasing incidence of serogroup B meningococcal disease in individuals 5-19 years old was clearly established before the campaign began. A 30% decrease in the case-fatality rate for individuals !20 years old was not significant ( ). The MCC P p .1598 vaccine program has been highly effective in Scotland, leading to substantial reductions in serogroup C meningococcal disease and meningococcal mortality, with no adverse effects on other groups.
Invasive infections due to Neisseria meningitidis are the most common cause of bacterial meningitis in the United Kingdom (UK) and are an important cause of morbidity and mortality around the world [1] . The peak age-specific attack rate for meningococcal disease occurs at 6 months of age, at the time when maternal (passive) immunity has largely disappeared and active immunity has yet to be developed. A second peak in incidence occurs in teenagers and young adults [2] . In the 1990s, of the 8 most common meningococcal serogroups, serogroups B and C accounted for 190% of all confirmed meningococcal infections in Scotland and the UK as a whole, with contributions from X, Y, W135, and nongroupable (i.e., usually noncapsular) serogroups making up ∼10% of the total [3] . Serogroup C disease, which is strongly associated with greater severity and poorer prognosis [4, 5] , showed a steadily increasing incidence in Scotland from 1996 onwards [6] . Subtyping analysis of confirmed cases of serogroup C meningococcal disease revealed that the majority were due to subtype C2a, which belongs to the virulent ET37 clonal group [7] . ET37 (sequence type [ST] 11) strains are characterized by a low carriage-to-invasive disease ratio and retain epidemic and cluster potential even at low carriage rates [8] .
In 1999, a new meningococcal conjugate serogroup C vaccine (MCC) became available to protect against serogroup C infection. Although polysaccharide-based vaccines have been available for immunization against serogroup C meningococcal disease since the 1970s, a relatively short duration of immune protection, combined with their ineffectiveness in young children, has largely restricted their use to outbreak management [9] . In 1999, in conjunction with the UK Department of Health, the Scottish Executive Health Department launched an MCC vaccine campaign that offered immunization to everyone !18 years of age and incorporated the vaccine into the routine infant immuni- Second phase  GP  GP  GP  GP  GP  GP  GP  GP  GP NOTE. In addition to the above, all full-time students commencing their first term at college or university in the autumn of 1999 were offered a single dose of serogroup A and serogroup C polysaccharide vaccine. Similarly, nonimmunized new students in the autumn of 2000 were reminded of the importance and continuing offer of conjugate MCC vaccine via their registered GP. GP , general practitioner or primary health care setting; MMR, measles, mumps, and rubella vaccine; No, vaccination program not active; Yes, vaccination program active.
a Sixteen-year-old and 17-year-old individuals who had left school were also offered vaccine (1 dose administered in the GP setting) in the spring of 2000 and thereafter as part of the second phase (or "mop-up") program in 2001.
zation program, and, by 2001, all individuals !20 years old had effectively been given the option of vaccination against serogroup C meningococcal disease [10, 11] . The timetable of the MCC vaccination program in Scotland is shown in table 1. In January 2002, eligibility for MCC vaccine was extended to include those 20-24 years old [12] . The feasibility of providing effective protection against a major cause of bacterial meningitis with use of an age-targeted conjugate vaccine campaign has been well illustrated by the success of Haemophilus influenzae type b (Hib) vaccine, introduced in the UK in 1992 [13] . Optimism based on the Hib experience, however, may be misplaced, because, unlike Hib, meningococcal invasive disease is not confined to a single serogroup [14] . Because immunization against serogroup C disease confers no cross protection against other serogroups, there remains the very real possibility of another meningococcal serogroup, such as B, W135, or Y taking up the "ecological niche" vacated by serogroup C [14, 15] , particularly because hypervirulent clonal groups (such as ET37) are not confined to serogroup C [8] . Additionally, the well established tendency of predominant serogroups to change over time in all populations that have been studied could further complicate the apparent impact of any large-scale vaccination campaign [8] . It was important, therefore, not to restrict the analysis to the immediate period after the intervention so that any changes in the pattern of disease that occurred independently of the vaccine program could be better elucidated. For this reason, the full 10-year period from 1994 through 2003 was selected for time-trend analysis with respect to the distribution of meningococcal disease by age group and serogroup.
METHODS
Incidence rates in Scotland by age group and serogroup for the period 1994-2003 were determined with use of census population denominators. Vaccine uptake data were collated for the schools program by the Information and Statistics Division of the Common Services Agency, National Health Service for Scotland, and estimates were obtained for the student population and for 16-18-year-old individuals no longer enrolled full-time in an educational institution from sample projections [16] . A patient with true vaccine failure was defined as one with a laboratory-confirmed case of invasive serogroup C infection with onset occurring 114 days after the last dose of vaccine scheduled for that age group. An estimate of vaccine effective- ness was determined by the screening method described by Farrington [17] .
Laboratory confirmation of meningococcal infection by the Scottish Meningococcus and Pneumococcus Reference Laboratory was determined on the basis of growth of the organism in blood and/or CSF cultures directly or results of a variety of nonculture methods (i.e., serological and molecular tests) [18] . All diagnostic laboratories in Scotland submitted invasive meningococcal isolates for serogroup determination and antibiotic susceptibility testing. For surveillance purposes, "meningococcal infections" comprise invasive infections due to N. meningitidis (including meningitis, septicemia, and other sterile-site infections) and conjunctivitis. Laboratory confirmation of infection is not always possible, and ∼30%-40% of cases are identified on the basis of clinical diagnosis only.
Statistical methods. Trends in the rates of infection were analyzed using Poisson regression models. The main aim of this analysis was to investigate trends in the incidence of the 2 major serogroups (B and C) in the 3 broad age groups (!5 years old, 5-19 years old, and у20 years old). The analysis was carried out in Splus, version 6 (Insightful) with use of the glm function and by treating the logarithm of the populations as an offset. The total numbers of cases of serogroups B and C infections were estimated by applying the proportions of those cases with typing information to the total number of diagnoses (laboratory plus clinical) by age group in each year. A x 2 test for proportions was used to compare the case-fatality rates among individuals who were !20 years old before the program with those who were !20 years old after the program (i.e., rates in 1994-1999 vs. those in [2000] [2001] [2002] [2003] .
RESULTS

Vaccination campaign.
Aggregate data for the schools program gave a total uptake rate of 88.7% of students (i.e., 686,138 individuals were immunized, from a total school roll of 773,808 individuals between the ages of 5 to 17 years old), and, on 21 June 2001, figures for preschool uptake were 92.9% of preschool-aged children for all of Scotland [16] . Estimates for individuals 16-18 years old who had continued in full-time education, which were made on the basis of data from several sample institutions, ranged from 60% to 70% of individuals, and, for the same age group no longer in education, uptake estimates ranged from 30% to 50% of the specified population. The midpoint of these ranges, combined with preschool and school program data, gives an estimated 85% uptake for the total population of individuals !20 years old, which was then used in the calculation of effectiveness. Taking account of 1 confirmed and 1 possible case of vaccine failure (the latter of which remained unconfirmed because of incomplete typing data) yielded a crude estimate for vaccine effectiveness of 99.23% (95% CI, 96.84-99.81).
Cases and incidence of meningococcal disease by age group and serogroup, 1998-2003. The number of serogroup C cases exceeded the number of serogroup B cases in Scotland for the first time in 1998 and contributed 150% of serogrouped cases of meningococcal disease in the first half of 1999 before beginning to decrease after the vaccine was introduced later that year (figure 1). For the year 2000, during which the bulk of the vaccination program was performed, the overall number of cases of meningococcal disease remained relatively high (355 cases in 2000 vs. 350 cases in 1999), despite a 32% reduction in serogroup C cases (table 2) . By the year 2001, the overall number of cases had decreased by 23%, with a greater reduction seen in the number of serogroup C infections (a 61.5% reduction for 2001, compared with 2000, or a 74% reduction between 1999 and 2001) (table 2). The decrease in incidence rate for serogroup C disease was most pronounced in the 5-19-year-old age group (table 3) , and, by the end of 2001, it was also clear that the total incidence of meningococcal disease in all 3 age groups was decreasing (figure 2 and table 3 ). Among subjects !5 years old, there was no significant P ! .001 change in the rate of serogroup B infection ( ) (figure P p .416 2A), but there was an increase in the rate of serogroup C infection in this age group, followed by a dramatic decrease from 15.8 incidents per 100,000 subjects in 1999 to 0.7 incidents per 100,000 subjects in 2001. A different trend pattern was observed for those subjects 5-19 years old ( ), among P ! .0001 whom there was a significant increase in the rate of serogroup B infection during the 8-year period from 1994 to 2001 (P ! ). Serogroup B incidence rates for the same age group for .0001 (table 3) . Among adults aged у20 years, the rates of infection were lower than they were for the other 2 age groups. Incidence rates for the 2 groups were quite similar between 1995 and 2000 ( ), and both age groups had the same P p .081 increasing trend ( ). For serogroups B and C, there P ! .0001 were notable decreases in the incidence rates in 2001, 2002, and 2003, although the decrease was much greater for serogroup C ( ). P ! .0001 Mortality. For the majority of the study period under consideration (specifically, 1995-2002) , the annual case-fatality rate for meningococcal disease has remained relatively stable, at 5%-8% ( figure 3 ). This overall stability, however, obscures a yearly increase in the case-fatality rate for patients with serogroup C infections that reached a peak of 29% in 2001 and which decreased to 0% by 2003. Case-fatality rates for those у20 years old followed a similar trend, decreasing rapidly after . By 2003, the overall casefatality rate had decreased to its lowest level in 10 years and, at 2.5%, was equivalent to that seen in 1994, at the start of the study period.
DISCUSSION
MCC vaccine was licensed for use in the UK on the basis of safety assessments and serological evidence of protectiveness [19, 20] and without formal efficacy studies. The vaccination campaign, introduced in 1999, took place in the context of an increasing incidence of serogroup C meningococcal disease in the UK as a whole, a form of meningococcal disease that is distinguished by a high mortality rate and low carriage-toinvasive disease ratio [8, 21] . As has been shown in other UK studies [10, 22] , MCC vaccine has proven to be a highly effective intervention in individuals !20 years old and has dramatically reduced serogroup C meningococcal disease in this age group in Scotland.
Variations over time for any disease under surveillance are, of course, subject to changes in reporting practice, and there is evidence to suggest that ascertainment rates did vary for these reasons in England and Wales during the period 1989-1995 [23] . Although an increasing and understandable reluctance by clinicians to undertake lumbar puncture procedures where avoidable has diminished the number of CSF samples available for culture, this has been more than offset by the introduction of new technologies and nonculture techniques [24] . Scotland's relatively small population also means that it is feasible for a central reference laboratory to process all samples obtained from patients with suspected meningococcal disease, which helps to maintain consistency in reporting practices over time [18] .
Although it is well established that meningococcal serogroups vary over time in terms of their respective predominance in any population [8, 25] , the marked reduction in the incidence of serogroup C disease and the reversal of the trend of an increasing number of serogroup C cases in the late 1990s was contemporaneous with the timing and targeting of the vaccine program. Although an accurate estimation of vaccine effectiveness should ideally be derived separately for different age groups, the small numbers that have arisen in the short time since implementation of the program make this impractical. The crude estimate of 99.23% that was obtained with the available data compares well with previously published results for England and Wales [22, 26] , although the high sensitivity of estimates derived from screening methods to age-dependant variability limits the reliability of this result [17] .
Shifts in the epidemiology of meningococcal disease towards older age groups, accompanied by a high degree of clonality among typed strains, has been cited as evidence of a shift from an endemic model of disease to a more epidemic one [27] . The UK experience, in the late 1990s, of an increasing burden of serogroup C meningococcal disease and increasing incidence rates in older age groups is suggestive of such a shift, with all the attendant public health implications of an increased likelihood of outbreaks and more-severe disease. The virtual elimination of serogroup C disease in target age groups by 2002 and a continuing decrease in adult incidence rates in the wake of the MCC campaign highlight the potential of populationlevel vaccine intervention to significantly and favorably influence the epidemiology of a complex disease, such as invasive infection with meningococci.
As has also been the case in England and Wales [22] , the incidence of serogroup B meningococcal disease, both in subjects aged 5-19 years old and those aged у20 years old, has been increasing steadily from 1998 through 2001. Excepting the years 1997 and 1998, this increase in Scotland has evidently been ongoing since at least 1994 (figure 2B). Such long-term gradual change is far more likely to be a reflection of normal cyclical variation than of any compensatory increase in serogroup B disease, either through occupying the 'ecological niche' vacated by serogroup C or by a form of serogroup switching [28] . This would be consistent with experience with the Hib conjugate vaccine, in that incidence of infection with non-type b strains of H. influenzae was not seen to increase after implementation of the vaccine program [13] , although their much-reduced pathogenicity, in contrast to that of non-sero- Table 3 . Incidence rates (IRs) per 100,000 subjects and 95% CIs for meningococcal disease in Scotland, 1994-2003, based on estimated no. of total cases, by age group and meningococcal serogroup. group C meningococcal disease, makes it difficult to make direct comparisons between the 2 programs. Furthermore, whatever the real explanation behind the increasing incidence of serogroup B meningococcal disease may have been, the trend has not continued after 2001 for either those у20 or 5-19 years old (figure 2). Prior to the MCC vaccination program, the incidence of serogroup C disease was increasing in Scotland [6] , a trend that began in the mid-1990s and which was also seen in the UK and the rest of Europe [29] . Serogroup C meningococcal disease is known to be associated with higher rates of mortality and long-term sequelae than is serogroup B disease [4, 21] , and young adults in particular account for a disproportionate number of cases. The high incidence of serogroup C infection in the 5-19-year-old age group in 1998, followed by dramatic reductions as the campaign progressed in 2000 and 2001 (figure 2B), suggests that the vaccine has been especially effective in this age group. The first year after the introduction of the MCC vaccination campaign also saw a steep decrease in serogroup C incidence among subjects !5 years old, compared with comparatively unchanged levels of serogroup B infection (figure 2A  and table 3) .
A relatively stable case-fatality rate for meningococcal disease in recent years in Scotland obscures a marked trend in the late 1990s towards an increasing mortality rate among adults ( figure  3 ). The virtual elimination of serogroup C meningococcal disease among individuals !5 years old has, without doubt, been a major element in the reduction of the overall case-fatality rate in this group, from ∼5% to !1% by 2001, although this was followed by a higher than usual number of serogroup Bassociated deaths in 2002, borne disproportionately by the youngest ages. In contrast, case fatality rates among individuals 120 years old, who were not included in the vaccine campaign, continued to increase and only started to decrease in 2001, as the burden of serogroup C disease was reduced, probably through reduced carriage and decreased opportunities for infection [30, 31] .
CONCLUSION
The new MCC conjugate vaccine has proven to be a highly effective intervention against serogroup C meningococcal disease in individuals !20 years old in Scotland. Although serogroup C disease may have begun to decrease as part of the normal cycle of changing predominance, the significant sharp downward trend in age-specific incidence for both target age groups after the introduction of the vaccine suggests that the program played a major role. Although there was an initial increase in the incidence of serogroup B disease in the older targeted age groups and, to a lesser extent, among adults, it has been possible to verify by means of trend analysis that the increase was established before the vaccine campaign began, which is similar to the situation in England and Wales [31] . There is clear evidence also that the MCC program may also have helped to reduce serogroup C disease across all age groups and that the benefits have not been restricted to target groups.
This finding is in keeping with recent modeling work on MCC vaccine, in which targeting the whole population was only marginally better in terms of a reduction in the number of cases than was a program for all individuals !21 years old [32] .
Previously, the only immunoprophylactic measures against meningococcal disease were polysaccharide vaccines that, despite being of benefit in helping to contain outbreaks, are ineffective in very young children and do not provide lasting protection. The new conjugate serogroup C vaccine therefore represents a major step forward in efforts to combat a rare but life-threatening disease. The recent extension of the MCC campaign in 2002 to include individuals 20-24 years old has, in all likelihood, been to the benefit of the wider population, because the available reservoirs of infection and carriage maintain their downward trend. Serogroup-specific vaccination programs for meningococcal disease will continue to require close monitoring of their epidemiological impact because of the mobility of genetic material between meningococci and the nonexclusivity of disease to any one serogroup. Additionally, the often-observed low carriage rate-to-disease ratio of serogroup C meningococcal disease [33] means that a possible future resurgence of disease cannot be easily discounted, and the MCC vaccine is likely to continue to play a key preventive role for the foreseeable future.
